Igenica Completes $24M Financing Round

Igenica, Inc., a Burlingame, CA-based biopharmaceutical company developing innovative antibody-based cancer medicines, has completed a $24m Series B financing round.
The round was led by The Column Group, OrbiMed Advisors and 5AM Ventures.
The financing will allow the company to expand and accelerate drug discovery and development efforts. 
To reach this target, Igenica uses two technology platforms: 
– sTAg, designed to discovering and prioritizing novel tumor antigens;
– iTAb, a functional in vivo antibody screening approach.



Join the discussion